Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma.

Abstract

PURPOSE To describe a case series of neovascular glaucoma (NVG) caused by central retinal vein occlusion (CRVO) that was treated with intravitreal bevacizumab (IVB; Avastin). DESIGN Retrospective interventional case series. METHODS Six consecutive patients with NVG and a refractory, symptomatic elevation of intraocular pressure (IOP) and pronounced anterior segment congestion received IVB (1.25 mg/0.05 ml). Diode laser cyclophotocoagulation was carried out only if pressure was controlled insufficiently by topical medication. Follow-up examinations occurred at four to 16 weeks. RESULTS IVB resulted in a marked regression of anterior segment neovascularization and relief of symptoms within 48 hours. IOP decreased substantially in three eyes; in the other three eyes, adjuvant cyclophotocoagulation was necessary. No side effects were observed. Panretinal photocoagulation (PRP) was performed as soon as feasible, five to 12 weeks after IVB treatment. CONCLUSION IVB leads to a rapid regression of iris and angle neovascularization and should be investigated more thoroughly as an adjunct in the management of NVG.

05010015020072008200920102011201220132014201520162017
Citations per Year

742 Citations

Semantic Scholar estimates that this publication has 742 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Iliev2006IntravitrealB, title={Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma.}, author={Milko E. Iliev and Diego Domig and Ute Wolf-Schnurrbursch and Sebastian Wolf and Gian-Marco Sarra}, journal={American journal of ophthalmology}, year={2006}, volume={142 6}, pages={1054-6} }